Literature DB >> 24402639

A novel diagnostic method targeting genomic instability in intracystic tumors of the breast.

Masahiro Oikawa1, Hiroshi Yano, Megumi Matsumoto, Ryota Otsubo, Kenichiro Shibata, Tomayoshi Hayashi, Kuniko Abe, Naoe Kinoshita, Koh-ichiro Yoshiura, Takeshi Nagayasu.   

Abstract

BACKGROUND: Even after needle biopsy, the preoperative differential diagnoses of intracystic tumors of the breast are challenging because of their nonspecific radiological characteristics and subtle cytological and histological appearance. The aim of this study is to investigate a novel diagnostic method, targeting genomic instability (GIN) in intracystic tumors of the breast, using tumor DNA from samples obtained by fine-needle aspiration biopsy (FNAB).
METHODS: Thirteen consecutive intracystic tumors of the breast, including five cancers and eight benign tumors, were studied. Three FNAB passages per tumor were used for array comparative genomic hybridization (aCGH) analysis to quantify GIN in each tumor. Tumor DNA from the main tumor, taken from formalin-fixed, paraffin-embedded (FFPE) blocks corresponding to FNAB samples, was also analyzed to compare cytogenetic profiles between these sample types.
RESULTS: After three FNAB passages, an average of 7.09 μg (0.24-25.0 μg) of DNA was obtained. The quality of the DNA and the aCGH data was excellent, as judged by the mean derivative log ratio spread (DLRSpread) of 0.22 (0.15-0.29). The cytogenetic profiles of paired FNAB and main tumor FFPE samples were highly similar, with an average concordance rate of 97.7 % (81.2-100 %). aCGH analysis from FNAB samples showed significantly more GIN in cancers than in benign tumors, with mean frequencies of aberrant chromosomal regions of 17.5 and 0.34 %, respectively (Wilcoxon's rank sum test, P = 0.0016).
CONCLUSIONS: Our novel diagnostic method, which targets GIN, can clearly distinguish cancers from benign tumors of breast intracystic lesions with minimal invasion, thereby avoiding the need for surgical excisional biopsy.

Entities:  

Mesh:

Year:  2014        PMID: 24402639     DOI: 10.1007/s12282-013-0516-9

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  3 in total

Review 1.  Genome evolution in ductal carcinoma in situ: invasion of the clones.

Authors:  Anna K Casasent; Mary Edgerton; Nicholas E Navin
Journal:  J Pathol       Date:  2016-11-27       Impact factor: 7.996

Review 2.  Ductal Carcinoma in Situ Biomarkers in a Precision Medicine Era: Current and Future Molecular-Based Testing.

Authors:  Kevin Shee; Kristen E Muller; Jonathan Marotti; Todd W Miller; Wendy A Wells; Gregory J Tsongalis
Journal:  Am J Pathol       Date:  2018-10-29       Impact factor: 4.307

3.  Mutational profiling of micro-dissected pre-malignant lesions from archived specimens.

Authors:  Daniela Nachmanson; Joseph Steward; Huazhen Yao; Adam Officer; Eliza Jeong; Thomas J O'Keefe; Farnaz Hasteh; Kristen Jepsen; Gillian L Hirst; Laura J Esserman; Alexander D Borowsky; Olivier Harismendy
Journal:  BMC Med Genomics       Date:  2020-11-18       Impact factor: 3.063

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.